{"id":211968,"date":"2025-04-21T03:10:04","date_gmt":"2025-04-21T08:10:04","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/04\/the-who-bacterial-priority-pathogens-list-2024-a-prioritisation-study-to-guide-research-development-and-public-health-strategies-against-antimicrobial-resistance"},"modified":"2025-04-21T03:10:04","modified_gmt":"2025-04-21T08:10:04","slug":"the-who-bacterial-priority-pathogens-list-2024-a-prioritisation-study-to-guide-research-development-and-public-health-strategies-against-antimicrobial-resistance","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/04\/the-who-bacterial-priority-pathogens-list-2024-a-prioritisation-study-to-guide-research-development-and-public-health-strategies-against-antimicrobial-resistance","title":{"rendered":"The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance"},"content":{"rendered":"<p style=\"padding-right: 20px\"><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/the-who-bacterial-priority-pathogens-list-2024-a-prioritisation-study-to-guide-research-development-and-public-health-strategies-against-antimicrobial-resistance2.jpg\"><\/a><\/p>\n<p>The 2024 WHO BPPL is a key tool for prioritising research and development investments and informing global public health policies to combat AMR. Gram-negative bacteria and rifampicin-resistant <i>M tuberculosis<\/i> remain critical priority pathogens, underscoring their persistent threat and the limitations of the current antibacterial pipeline. Focused efforts and sustained investments in novel antibacterials are needed to address AMR priority pathogens, which include high-burden antibiotic-resistant bacteria such as <i>Salmonella<\/i> and <i>Shigella<\/i> spp, <i>N gonorrhoeae<\/i>, and S aureus.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The 2024 WHO BPPL is a key tool for prioritising research and development investments and informing global public health policies to combat AMR. Gram-negative bacteria and rifampicin-resistant M tuberculosis remain critical priority pathogens, underscoring their persistent threat and the limitations of the current antibacterial pipeline. Focused efforts and sustained investments in novel antibacterials are needed [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1495],"tags":[],"class_list":["post-211968","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-health"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/211968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=211968"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/211968\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=211968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=211968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=211968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}